must have a high therapeutic index. Lestaurtinib was well tolerated in phase 1 and 2 studies, and therefore has already passed its first important test. Nevertheless, inhibition of JAK2 raises concerns, since JAK2 is required for signaling by the receptors for erythropoietin, thrombopoietin, and in part, G-CSF. In this respect, it is encouraging that cells carrying JAK2-V617F were more sensitive to the inhibition of lestaurtinib than cells with WT JAK2. Conversely, cells from MPD patients negative for JAK2-V617F were also inhibited by lestaurtinib. This could be interpreted to mean that activation of JAK2 signaling is a common pathway of pathogenesis in MPDs. Alternatively, lestaurtinib may have additional beneficial "off-target" effects by inhibiting other, as-yet-unknown kinases that act as cooperating cellular signaling pathways.
The work by Hexner and colleagues shows that lestaurtinib can be added to a rapidly growing list of small molecules with inhibitory effects against JAK2. Information about the structure of the complete human kinome, in conjunction with high-throughput screening platforms, may reveal other hidden gems and allow further expansion of targeted cancer therapeutics. The discovery of JAK2 mutations in MPDs has initiated an exciting new phase for clinicians and basic scientists interested in MPDs, and has already substantially improved diagnostics and advanced our knowledge of MPD pathogenesis. In fewer than 3 years since their discovery, there has developed the exciting prospect that patients with MPDs may soon benefit from targeted treatment for their disease. 
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SNPing away at sickle cell pathophysiology ----------------------------------------------------------------------------------------------------------------
Martin H. Steinberg BOSTON UNIVERSITY SCHOOL OF MEDICINE
In this issue of Blood, Ashley-Koch and coworkers report that, in sickle cell disease-related pulmonary hypertension, SNPs in several genes of the TGF-␤/ BMP superfamily are associated with this complication.
S
ickle cell anemia, a common hemolytic anemia caused by homozygosity for the sickle hemoglobin mutation (glu6val) in the ␤-globin gene (HBB), is a characteristic Mendelian monogenic disease. Nevertheless, it is clinically heterogenous, resembling a multigenic trait. Although environment must account for part of this variability-in developing countries with little access to health care, death in childhood is frequent-even in countries with reasonable health care systems, clinical variability is striking. During the past 5 years, genetic association studies have focused on understanding the basis for this variability by linking single nucleotide polymorphisms (SNPs) in genes that might affect the pathophysiology of disease with disease subphenotypes. As shown in the figure, these subphenotypes include: stroke, priapism, leg ulcers, osteonecrosis, renal failure, bacteremia, and cholelithiasis; many associations, especially with SNPs in genes of the TGF-␤/ BMP pathway, have been found. The association of these polymorphisms with disease phenotypes is likely to reflect the modulation of sickle vasculopathy. Now, the first reported study of its kind in sickle cell pulmonary hypertension, an abnormality found in about a third of adults with sickle cell anemia, and one that portends a high risk of very near term mortality, 1 adds some SNPs in the TGF-␤/BMP pathway to this list. Although the number of patients examined was small, and although one might quibble about the selection of cases and controls and certain analytical issues, it is satisfying that some results recapitulate observations made in other disease subphenotypes like stroke, 2 and further implicate the TGF-␤/ BMP superfamily in the pathophysiology of disease. Other teams are studying larger groups of patients, and we should soon see if the results of these studies are confirmed. The mechanisms by which perturbation of this pathway might modulate the disease remain obscure.
Genetic association studies to date are based on searching for SNPs in candidate genes. That is, each gene was chosen because of its potential importance in this disease. As a result, the positive results are gratifying, but represent a self-fulfilling prophecy. Unraveling the genetic basis for the clinical heterogeneity of sickle cell anemia will require genomewide association studies in which upwards of a half million SNPs-279 were tested in this 
. This approach relieves the investigator of having to conjure up candidate genes, and will lead to unexpected and often inexplicable findings, as have been reported for diabetes, a prime example of a multigenic trait. 3 To query such a large number of SNPs, patient samples must be substantial and the analytical approach must be rigorous. Nevertheless, many smaller studies could be aggregated to provide a patient base that is sufficiently large and diverse to validate the findings.
The near-term results of these studies will be an additional means of predicting outcomes and tailoring treatment. A longer-term goal is the identification of hitherto unsuspected disease modulators, like the TGF-␤/BMP pathway, that might be amenable to modulation and therefore suggest new avenues of drug development. MAYO CLINIC In this issue of Blood, Kelly and colleagues provide a possible solution to poor thymic function and prolonged immune deficiency following allogeneic BMT by demonstrating the additive benefit of combining KGF with androgen blockade to speed recovery of thymic function and reconstitution of functional T cells after BMT.
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High-TECh thymus ----------------------------------------------------------------------------------------------------------------Eugene Kwon
T he thymus is a dynamic organ with regard to both the lymphoid and stromal compartments. The 3-dimensional thymic stromal compartment, composed primarily of cortical and medullary thymic epithelial cells (TECs), fibroblasts, and endothelial cells, directly supports thymocyte development and selection. 1 Myeloablative conditioning prior to hematopoietic stem-cell transplantation (HSCT) damages and depletes TECs. Because T-cell reconstitution and the generation of a broad T-cell repertoire require factors supplied by TECs, prolonged T-cell immune deficiency due to TEC injury predisposes patients to infections. Adults who undergo allogeneic HSCT, and who typically have poor age-and chemotherapy-related TEC support of thymopoiesis, are especially vulnerable. 2 Low TEC levels would impede T-cell reconstitution, regardless of the number of stem and thymic progenitor cells infused.
Hormonal factors can inhibit thymopoiesis. Androgens (eg, testosterone) strongly suppress thymopoiesis via effects on TECs and other androgen receptor-bearing cells in the thymus. Physical castration of old mice can reverse thymic atrophy linked to age-related increases in androgen levels. 3 In addition, androgen ablation has been reported to enhance thymopoiesis and reduce costimulatory thresholds for peripheral T-cell activation, possibly resulting in enhanced host immunity. 4 Consistent with this, initial clinical studies have indicated that pretransplant castration may improve patient thymopoiesis and T-cell recovery. 5, 6 TECs also may be positively regulated by thymic proteins. Keratinocyte growth factor (KGF), also known under the generic drug name palifermin, is a member of the fibroblast growth factor family that binds FGFR2-IIIb expressed by TECs. Studies in mice and rhesus macaques have demonstrated that thymic injury and T-cell deficiency can be partially ameliorated by KGF pretreatment; however, maximal benefit was not observed until relatively long after bone marrow transplantation (BMT). 7, 8 The individual thymopoieitc effects of KGF and physical castration, and the broad distribution of cognate receptors for KGF as well as androgen within thymic tissues, led the authors to pretreat allo-BMT recipients with both KGF to induce TEC mitogenesis and a chemical luteinizing hormone-releasing hormone supraagonist, leuprolide (Lupron; TAP Pharmaceutical Products, Lake Forest, IL), to block the androgen-inhibitory pathway. Prior to conditioning, these agents, when given together but not individually, normalized TEC subset numbers and thymic architecture, led to supranormal thymopoiesis and accelerated peripheral CD4/ CD8 T-cell reconstitution, facilitated CD8 T cell-mediated clearance of a live pathogen, and augmented a CD4 T cell-dependent B-cell humoral response. Distinct TEC subsets were protected by each reagent. Importantly, palifermin is approved for use in HSCT patients to prevent mucositis, and various chemical luteinizing hormone-releasing hormone supra-agonists including leuprolide acetate (ie, Lupron) have been used for several decades to treat prostate cancer. Each agent is under separate investigation in clinical studies to determine its potential for enhancing T-cell reconstitution in patients undergoing HSCT. While future clinical trials arising from these provocative preclinical studies will need to be performed to determine whether the incidence of infectious complications can be diminished without adverse effects on graftversus-host disease or tumor recurrence, it is likely that multimodal therapy targeting TEC subsets and other thymic stromal cells holds the key to reducing the profound immune deficiency that accompanies allogeneic HSCT.
Conflict-of-interest disclosure: The author declares no competing financial interests. ■ For personal use only. on June 10, 2017. by guest www.bloodjournal.org From
